IP Library Patent Application 12722477
Patent Application
App. No. 12/722,477

NOVEL RECEPTOR THAT BINDS CTLA-8

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/722,477
Abstract

Isolated receptors for CTLA-8, DNAs encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to inhibit an immune response.

Claims (23)

1 . An isolated DNA selected from the group consisting of:

(a) a DNA having a nucleotide sequence encoding an amino acid sequence of amino acids 1 through 322 of SEQ ID NO.: 2; and

(b) DNA molecules capable of hybridization to the clones of (a) under stringent conditions and which encode CTLA-8R capable of binding CTLA-8.

2 . An isolated DNA according to claim 1 which encodes a soluble CTLA-8R.

3 . An isolated DNA selected from the group consisting of:

(a) a DNA having a nucleotide sequence encoding an amino acid sequence of amino acids 1 through 322 of SEQ ID NO.: 2; and

(b) DNA molecules encoding peptides that are at least about 70% identical in amino acid sequence to the amino acid sequence of SEQ ID NO:2.

4 . A recombinant expression vector comprising a DNA sequence according to claim 1 .

5 . A recombinant expression vector comprising a DNA sequence according to claim 2 .

6 . A recombinant expression vector comprising a DNA sequence according to claim 3 .

7 . A host cell transformed or transfected with an expression vector according to claim 4 .

8 . A host cell transformed or transfected with an expression vector according to claim 5 .

9 . A host cell transformed or transfected with an expression vector according to claim 6 .

10 . A process for preparing a CTLA-8R or an analog thereof, comprising culturing a host cell according to claim 7 under conditions promoting expression.

11 . A process for preparing a CTLA-8R or an analog thereof, comprising culturing a host cell according to claim 8 under conditions promoting expression.

12 . A process for preparing a CTLA-8R or an analog thereof, comprising culturing a host cell according to claim 9 under conditions promoting expression.

13 . An isolated and purified biologically active CTLA-8 receptor (CTLA-8R) protein.

14 . An isolated and purified CTLA-8R protein according to claim 13 , consisting essentially of human CTLA-8R.

15 . An isolated and purified CTLA-8R according to claim 13 , consisting essentially of soluble CTLA-8R.

16 . A composition comprising a CTLA-8R protein according to claim 13 , and a suitable diluent or carrier.

17 . A method for regulating an immune or inflammatory response in a mammal, comprising administering an effective amount of a composition according to claim 16 .

18 . An assay method for detection of CTLA-8 and homologs thereof, or CTLA-8R and homologs thereof, or the interaction thereof, comprising use of a protein composition according to claim 16 .

19 . Antibodies immunoreactive with CTLA-8R.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 19, 2013
From: AMGEN INC.
To: KIRIN-AMGEN, INC.
Reel/Frame 030045/0876 →